News
After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.
The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...
Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
Weight loss injections work by making you feel fuller and less hungry. There are plenty of weight loss medication options to ...
Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...
Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results